|
AP3M2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.60669999999175E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.54320999999902E-05 |
| Normal-vs-Stage2 |
3.078400E-01 |
| Normal-vs-Stage3 |
1.72030000000767E-06 |
| Normal-vs-Stage4 |
1.11369999888922E-08 |
| Stage1-vs-Stage2 |
7.321900E-03 |
| Stage1-vs-Stage3 |
3.479600E-01 |
| Stage1-vs-Stage4 |
2.798300E-02 |
| Stage2-vs-Stage3 |
5.939300E-03 |
| Stage2-vs-Stage4 |
4.030100E-04 |
| Stage3-vs-Stage4 |
1.674250E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.46829999562115E-08 |
| Normal-vs-AfricanAmerican |
2.277600E-02 |
| Normal-vs-Asian |
1.023290E-03 |
| Caucasian-vs-AfricanAmerican |
2.596400E-01 |
| Caucasian-vs-Asian |
3.108200E-01 |
| AfricanAmerican-vs-Asian |
7.566000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.12419999999769E-05 |
| Normal-vs-Female |
1.71955999999085E-05 |
| Male-vs-Female |
5.678200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.07110000000066E-05 |
| Normal-vs-Age(41-60Yrs) |
3.83650000002067E-06 |
| Normal-vs-Age(61-80Yrs) |
2.449400E-04 |
| Normal-vs-Age(81-100Yrs) |
1.096750E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.917400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.296200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.641200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.147600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.663400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.621020E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.544300E-03 |
| Classical-VS-Follicular |
8.391900E-04 |
| Classical-VS-Other |
4.498600E-01 |
| Classical-VS-Normal |
2.82450000055334E-07 |
| Tall-VS-Follicular |
4.79520000040701E-07 |
| Tall-VS-Other |
4.605000E-01 |
| Tall-VS-Normal |
3.31649996354599E-09 |
| Follicular-VS-Other |
1.120820E-01 |
| Follicular-VS-Normal |
2.594400E-01 |
| Other-VS-Normal |
6.156400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.950200E-04 |
| Normal-vs-N1 |
2.91260005003124E-09 |
| N0-vs-N1 |
3.605400E-04 |
|
|
